Enimmune Corporation (TPEX:6564)

Taiwan · Delayed Price · Currency is TWD

16.45

+0.20 (1.23%)

Oct 8, 2026, 2:35 PM CST

Market Cap	1.19B -21.3%
Revenue (ttm)	53.45M +26.6%
Net Income	-120.88M
EPS	-1.68
Shares Out	72.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,194
Open	15.95
Previous Close	16.25
Day's Range	15.95 - 16.55
52-Week Range	14.90 - 23.90
Beta	0.24
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 38

Stock Exchange Taipei Exchange

Ticker Symbol 6564

Full Company Profile

Financial Performance

In 2025, Enimmune's revenue was 48.19 million, an increase of 20.74% compared to the previous year's 39.92 million. Losses were -164.35 million, 4.32% more than in 2024.

Financial Statements